SCHEMBL2912868

SCHEMBL2912868

CC1CN(Cc2ccccc2)Cc2ccc(Cl)nc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.42
ESR1 P03372 1/20 0.41
ESR2 Q92731 1/20 0.41
MC4R P32245 1/20 0.41
CYP1A2 P05177 1/20 0.40
FUCA1 P04066 2/20 0.39
SLC6A12 P48065 1/20 0.39
SIGMAR1 Q99720 3/20 0.39
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
PNMT P11086 1/20 0.38
HTR1A P08908 1/20 0.37
ADRA2A P08913 1/20 0.37
ADRA2B P18089 1/20 0.37
ADRA2C P18825 1/20 0.37
DRD4 P21917 1/20 0.37
SLC6A2 P23975 1/20 0.37
HTR2C P28335 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29883093 1.00 ACHE (0.42) ACHEESR1ESR2MC4RCYP1A2
SCHEMBL28693977 0.84 ESR1 (0.40) ACHEESR1ESR2MC4RCYP1A2
SCHEMBL28688459 0.83 MC4R (0.41) ACHEESR1ESR2MC4RCYP1A2
SCHEMBL29883450 0.83 ESR1 (0.39) ACHEESR1ESR2MC4RCYP1A2
SCHEMBL28675954 0.83 ESR1 (0.39) ACHEESR1ESR2MC4RCYP1A2
SCHEMBL2908443 0.81 ACHE (0.36) ACHEESR1ESR2MC4RCYP1A2
SCHEMBL31569135 0.81 ACHE (0.42) ACHEESR1ESR2MC4RFUCA1
SCHEMBL28689000 0.80 ESR1 (0.39) ACHEESR1ESR2MC4RCYP1A2
SCHEMBL2109285 0.79 CYP1A2 (0.39) ACHEESR1ESR2MC4RCYP1A2
SCHEMBL2909937 0.79 SLC2A1 (0.41) ACHECYP1A2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317735-A1 HYDROISOQUINOLINE OR HYDRONAPHTHYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE HOFFMANN-LA ROCHE INC. (US) 2024-09-26 US disclosed
CN-115835910-A Hydrogenated isoquinoline or naphthyridine compounds for the treatment of autoimmune diseases 豪夫迈·罗氏有限公司 2023-03-21 CN disclosed
CN-113880866-B Aza-tetrahydronaphthyridine compound, preparation method thereof, pharmaceutical composition and application thereof 上海维申医药有限公司 2022-09-27 CN disclosed
CN-113880866-A Aza-tetrahydronaphthyridine compound, preparation method thereof, pharmaceutical composition and application thereof 上海维申医药有限公司 2022-01-04 CN disclosed
EP-2789338-A2 Condensed pyridine derivate and use thereof Takeda Pharmaceutical Company Limited (JP) 2014-10-15 EP disclosed
US-20100266504-A1 CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-21 US disclosed
EP-2216023-A1 CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-08-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317735-A1 HYDROISOQUINOLINE OR HYDRONAPHTHYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE HRH3, H1-3, HRH4 ACHE 3363/4885ESR1 4492/4885ESR2 3549/4885
US-20100266504-A1 CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF HTR2C, HTR5A, HTR3C ACHE 2687/4885ESR1 1388/4885ESR2 2061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.